Pulse Biosciences

Yahoo Finance • 16 days ago

Pulse Biosciences is Now Oversold (PLSE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 3 months ago

Pulse Biosciences reports success in thyroid nodule treatment study

HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.11 billion market cap medical technology company with strong liquidity metrics, announced that a first-in-human clinical feasibility study has demonstrated the effectiveness of... Full story

Yahoo Finance • 4 months ago

Pulse Biosciences outlines initial percutaneous electrode revenue and IDE milestones while expanding nsPFA clinical programs

Earnings Call Insights: Pulse Biosciences (PLSE) Q2 2025 MANAGEMENT VIEW * Paul Arthur LaViolette, President and CEO, described the ongoing expansion across three market development programs, emphasizing the clinical and commercial pro... Full story

Yahoo Finance • 2 years ago

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., November 15, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment o... Full story

Yahoo Finance • 2 years ago

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

Pulse Biosciences will host a conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023 HAYWARD, Calif., November 10, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

HAYWARD, Calif., May 18, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today anno... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript May 11, 2023 Pulse Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.23 EPS, expectations were $-0.22. Operator: Good afternoon, ladies and gentl... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript March 30, 2023 Operator: Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences' Fourth Quarter 2022 Earnings Conference Call. At this time all particip... Full story

Yahoo Finance • 4 years ago

Stock rebound uncertain for U.S. biotechs as risks multiply for investors

U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.... Full story

Yahoo Finance • 4 years ago

Pulse Biosciences Reports First Quarter 2022 Financial Results

HAYWARD, Calif., May 11, 2022--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial... Full story

Yahoo Finance • 4 years ago

PLSE DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action – PLSE

NEW YORK, April 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive... Full story

Yahoo Finance • 4 years ago

DEADLINE ALERT for SPWR, PLSE, BFLY, GWGH: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., April 15, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 4 years ago

SPWR, PLSE & MP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Upcoming Class Action Deadlines and to Contact the Firm

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy o... Full story

Yahoo Finance • 4 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acutus, Pulse, SunPower, and Butterfly and Encourages Investors to Contact the Firm

NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Acutus Medical, Inc. (NA... Full story

Yahoo Finance • 4 years ago

PLSE FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Pulse Biosciences, Inc. Investors with Losses to Secure Counsel Before Important April 18 Deadline in Securities Class Action – PLSE

NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive... Full story

Yahoo Finance • 4 years ago

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc. (PLSE)

LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 18, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased... Full story

Yahoo Finance • 4 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fennec, Astra, Acutus, and Pulse and Encourages Investors to Contact the Firm

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fennec Pharmaceuticals,... Full story

Yahoo Finance • 4 years ago

PLSE FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Pulse Biosciences, Inc. Investors With Losses Over $100K to Secure Counsel Before Important April 18 Deadline in Securities Class Action – PLSE

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive... Full story

Yahoo Finance • 4 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pulse, SunPower, Butterfly, and GWG and Encourages Investors to Contact the Firm

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Pulse Biosciences, Inc.... Full story

Yahoo Finance • 4 years ago

Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results

HAYWARD, Calif., March 31, 2022--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financi... Full story